The Application Value of CT Perfusion Imaging Combined with suPAR and Mac-2BP in the Prognosis Evaluation of Branch Atherosclerotic Disease: a prospective study DOI Creative Commons
Shengjie Hu, Shengqi Fu, Haoran Li

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 18, 2024

Abstract Background and objective Branch atheromatous disease (BAD) is highly susceptible to early neurological deterioration (END), resulting in a poor prognosis for patients. However, there no reliable serum biomarker BAD. The aim of this study investigate the correlation between CT perfusion imaging combined with soluble urokinase plasminogen activator receptor (suPAR) Mac-2 binding protein (Mac-2BP) END patients Methods Between June 2019 March 2024, We prospectively recruited eligible BAD admitted neurology department. defined as an increase ≥ 2 points total score National Institutes Health Stroke Scale (NIHSS) or 1 point exercise within 72 hours after admission; Using modified Rankin scale (mRS) evaluate clinical outcomes at 90 days, were mRS scores 3 days onset; Define cerebral damage based on CTP parameters. Compare suPAR Mac-2BP levels non patients, well different outcomes. Use multivariate logistic regression analyze independent influencing factors BAD, use receiver operation characteristic curve (ROC) accuracy predicting Results A 176 included, which had significant damage, 42 developed END, 47 onset. Multivariate analysis showed that (OR 0.706, 95% CI 0.573 ~ 0.868)、Mac-2BP 0.674,95% 0.486 0.935),、Cerebral impairment 6.083, 1.318 28.080)、deep WMHs 1.967, 0.884 2.751) deep CMBs 2.249, 1.113 3.126) are risk BAD; suPAR(OR 6.702,95% 2.776 16.182)、Mac-2BP 1.707, 1.132 2.576)、NIHSS 0.529, 0.339 0.824)、END 1.286, 1.016 1.628)、Cerebral 12.873, 2.744 60.385) basal ganglia EPVS 1.509, 1.019 2.233) ROC shows AUC detecting 0.8844 (95% CI: 0.822–0.947), sensitivity specificity 76.2% 85.1%, respectively; detection two indicators was 0.8742 0.810 0.938), 74.5% 83.9%, respectively. Conclusions Among Cerebral impairment, suPAR, outcome days. Combined can help patient's condition predict prognosis.

Language: Английский

Role of Nanotechnology in Ischemic Stroke: Advancements in Targeted Therapies and Diagnostics for Enhanced Clinical Outcomes DOI Creative Commons
Virendra Kumar Yadav,

Rachna Gupta,

Abdullah Assiri

et al.

Journal of Functional Biomaterials, Journal Year: 2025, Volume and Issue: 16(1), P. 8 - 8

Published: Jan. 1, 2025

Each year, the number of cases strokes and deaths due to this is increasing around world. This could be work stress, lifestyles, unhealthy food habits, several other reasons. Currently, there are traditional methods like thrombolysis mechanical thrombectomy for managing strokes. The current approach has limitations, delayed diagnosis, limited therapeutic delivery, risks secondary injuries. So, a need some effective reliable management strokes, which help in early diagnosis followed by treatment Nanotechnology played an immense role recently, it emerged as transformative solution offering innovative diagnostic tools strategies. Nanoparticles (NPs) belonging classes, including metallic (metallic metal oxide), organic (lipids, liposome), carbon, can cross blood–brain barrier may exhibit potential various Moreover, these NPs have exhibited promise improving imaging specificity delivery precise drug real-time monitoring efficacy. Nanomaterials cerium oxide (CeO2) liposome-encapsulated agents neuroprotective properties that reduce oxidative stress promote neuroregeneration. In present article, authors emphasized significant advancements nanomedicine stroke, NPs-based systems, neuroregenerative therapies, multimodal advancements.

Language: Английский

Citations

1
Advances in nanoparticle-based therapeutics for ischemic stroke: Enhancing drug delivery and efficacy DOI Open Access
Peng Ji, Qingqing Xu, Jiahui Li

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 180, P. 117564 - 117564

Published: Oct. 13, 2024

Language: Английский

Citations

5
Methylprednisolone as Adjunct to Thrombectomy for Acute Intracranial Internal Carotid Artery Occlusion Stroke DOI Creative Commons
Chong Zheng,

Rongtong Li,

Chaoxiong Shen

et al.

JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(2), P. e2459945 - e2459945

Published: Feb. 18, 2025

Importance Patients with acute ischemic stroke (AIS) due to intracranial internal carotid artery (ICA) occlusion often have poor functional outcomes despite undergoing endovascular thrombectomy (EVT). Objective To investigate the effectiveness and safety associated intravenous methylprednisolone as adjunctive treatment EVT for patients AIS ICA occlusion. Design, Setting, Participants This was a post hoc analysis of MARVEL randomized, double-blind, placebo-controlled clinical trial conducted from February 9, 2022, June 30, 2023, at 82 centers across China 3-month follow-up. The primary enrolled 1680 large vessel within 24 hours last known well time in ICA, first segment middle cerebral (M1), or second (M2), whom 579 had Intervention Intravenous methylprednisolone, 2 mg/kg/d (maximum dose, 160 mg) 3 days plus vs placebo EVT. Main Outcomes Measures outcome independent ambulation 90 days, defined score 0 on modified Rankin Scale (range, [no symptoms] 6 [death]). Safety included death symptomatic hemorrhage (sICH) 48 hours, decompressive hemicraniectomy relieve midline-shift pressure after Results Among (median age, 69.0 years [IQR, 59.0-76.0 years]; 338 men [58.4%]), there were 286 group 293 group. proportion who achieved 90-day significantly higher than (151 284 [53.2%] 125 [42.7%]; adjusted risk ratio [RR], 1.27 [95% CI, 1.07-1.52]; P = .007). incidence sICH lower (26 277 [9.4%] 45 290 [15.5%]; RR, 0.55 0.35-0.87]; .01). rate compared (16 [5.6%] 29 [9.9%]; 0.54 0.30-0.98]; .04). No significant difference observed mortality between groups (methylprednisolone, 92 [32.4%] placebo, 111 239 [37.9%]; 0.84 0.67-1.05]; .13). Conclusions Relevance In this secondary randomized EVT, improved ambulation. These findings suggest that use an adjunct may hold promise option Trial registration ChiCTR.org.cn Identifier: ChiCTR2100051729

Language: Английский

Citations

0
Protein-based nano delivery systems focusing on protein materials, fabrication strategies and applications in ischemic stroke intervention: A review DOI
Chao Yan, Xiang Zhu, Yingying Ren

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 311, P. 143645 - 143645

Published: April 29, 2025

Language: Английский

Citations

0
Nanomedicine: Pioneering Advances in Neural Disease, Stroke and Spinal Cord Injury Treatment DOI Creative Commons

Borish Loushambam,

Sangeeta Yanglem,

Venkatraman Krishnaswami

et al.

Neuroglia, Journal Year: 2025, Volume and Issue: 6(1), P. 9 - 9

Published: Feb. 21, 2025

Background: Neurological disorders such as Alzheimer’s disease (AD), Parkinson’s (PD), stroke, and spinal cord injury (SCI) are significant global health challenges due to their complex pathology limited therapeutic options. Conventional treatments often fail efficiently cross the blood–brain barrier (BBB), leading poor bioavailability systemic toxicity. This narrative review explores potential of nanomedicine in addressing these limitations advancing targeted therapies for neural disorders. Methods: examines recent studies on use engineered nanoparticles (NPs), including liposomes, dendrimers, micelles, nanogels, drug delivery multifunctional theranostics diseases. It evaluates role promoting axon regeneration, reducing neuroinflammation, repairing damage. Additionally, innovative applications gene therapy RNA-based treatments, CRISPR-Cas9 RNA interference (RNAi), discussed. Challenges related toxicity, scalability, affordability, regulatory barriers highlighted, along with strategies address issues. Results: Nanoparticles have shown promise crossing BBB, delivering agents tissues, minimizing off-target effects. Emerging demonstrate versatility disease-specific challenges. However, unresolved issues long-term safety, manufacturing cost continue pose Conclusions: Nanomedicine offers a promising approach overcoming current treatment emphasizes need continued interdisciplinary efforts translational highlights improve outcomes quality life patients disorders, SCI.

Language: Английский

Citations

0
RVG-peptide-camouflaged iron-coordinated engineered polydopamine nanoenzyme with ROS scavenging and inhibiting inflammatory response for ischemic stroke therapy DOI
Heng Liu, Rengong Zhuo, Chao Zou

et al.

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: unknown, P. 136778 - 136778

Published: Oct. 1, 2024

Language: Английский

Citations

0
The Application Value of CT Perfusion Imaging Combined with suPAR and Mac-2BP in the Prognosis Evaluation of Branch Atherosclerotic Disease: a prospective study DOI Creative Commons
Shengjie Hu, Shengqi Fu, Haoran Li

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 18, 2024

Abstract Background and objective Branch atheromatous disease (BAD) is highly susceptible to early neurological deterioration (END), resulting in a poor prognosis for patients. However, there no reliable serum biomarker BAD. The aim of this study investigate the correlation between CT perfusion imaging combined with soluble urokinase plasminogen activator receptor (suPAR) Mac-2 binding protein (Mac-2BP) END patients Methods Between June 2019 March 2024, We prospectively recruited eligible BAD admitted neurology department. defined as an increase ≥ 2 points total score National Institutes Health Stroke Scale (NIHSS) or 1 point exercise within 72 hours after admission; Using modified Rankin scale (mRS) evaluate clinical outcomes at 90 days, were mRS scores 3 days onset; Define cerebral damage based on CTP parameters. Compare suPAR Mac-2BP levels non patients, well different outcomes. Use multivariate logistic regression analyze independent influencing factors BAD, use receiver operation characteristic curve (ROC) accuracy predicting Results A 176 included, which had significant damage, 42 developed END, 47 onset. Multivariate analysis showed that (OR 0.706, 95% CI 0.573 ~ 0.868)、Mac-2BP 0.674,95% 0.486 0.935),、Cerebral impairment 6.083, 1.318 28.080)、deep WMHs 1.967, 0.884 2.751) deep CMBs 2.249, 1.113 3.126) are risk BAD; suPAR(OR 6.702,95% 2.776 16.182)、Mac-2BP 1.707, 1.132 2.576)、NIHSS 0.529, 0.339 0.824)、END 1.286, 1.016 1.628)、Cerebral 12.873, 2.744 60.385) basal ganglia EPVS 1.509, 1.019 2.233) ROC shows AUC detecting 0.8844 (95% CI: 0.822–0.947), sensitivity specificity 76.2% 85.1%, respectively; detection two indicators was 0.8742 0.810 0.938), 74.5% 83.9%, respectively. Conclusions Among Cerebral impairment, suPAR, outcome days. Combined can help patient's condition predict prognosis.

Language: Английский

Citations

0